fda bpc 157 compounding category 2 list 1 vs. Category 2. The FDA's peptide update, explained. Category peptides are on the FDA's “difficult to compound” list, which effectively blocks licensed pharmacies from producing them. Category 1 means FDA's Overreach on Compounded Peptides
FDA's Overreach on Compounded Peptides You may have heard buzz about 14 peptides potentially returning to legal compounding. Here's what we know: HHS Secretary RFK Jr. stated his intention to move these peptides from FDA Category 2 Exciting news for peptides coming out of today's committee hearing! The FDA Pharmacy Compounding Advisory Committee voted 8 6 to recommend adding BPC 157 to the 503A Bulks List for use in compounding for FDA mulls compounding for peptides previously flagged over safety risks BioSpace This just in: The FDA is proposing to move 14 commonly used peptides from Category 2 to Category 1 on the compounding review list If finalized, this shift could significantly change FDA Removes Peptides from Category 2 List, Paving Way for Regulation Jonathan Cole posted on the topic LinkedIn
Pay in 4 interest-free payments of $6.00 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5

